Audentes Therapeutics, Inc. — Form D
Audentes Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2015-09-02. Industry: Biotechnology.
Offering
- Filed: 2015-09-02
- Form: D
- Accession: 0001628738-15-000001
- Industry: Biotechnology
- Exemptions: 06b
- Investors: 21
- Date of first sale: 2015-08-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-246838
Issuer
- Name: Audentes Therapeutics, Inc.
- CIK: 0001628738
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2012
- Address: 101 MONTGOMERY STREET, SUITE 2650, SAN FRANCISCO, CA, 94104
- Phone: 415-638-6556
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Louis G Lange | Director | San Francisco, CA |
| Matthew Patterson | Director | South San Francisco, CA |
| Matthew Patterson | Executive Officer | South San Francisco, CA |
| Jonathan Silverstein | Director | Chicago, IL |
| Jonathan Leff | Director | Ness Ziona, L3 |
| Thomas Woiwode | Director | San Francisco, CA |
| Louis Lange | Director | Palo Alto, CA |
| Kush Parmar | Director | San Francisco, CA |
| Steve Squinto | Director | Milwaukee, WI |
| Thomas Schuetz | Director | Cambridge, MA |
Other filings by this issuer (2)
More